Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Refractory post-thymectomy myasthenia gravis with onset at MGFA stage V: a case report.

Authors:
Rui-Qin Zhou Lin-Jun Li Qing-Chen Wu

J Cardiothorac Surg 2022 May 12;17(1):115. Epub 2022 May 12.

Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.

Background: Post-thymectomy myasthenia gravis (PTMG) is defined as thymoma patients without signs of myasthenia gravis (MG) pre-operation, but develop MG after radical surgical resection. PTMG might be misdiagnosed not only because of its rare incidence, but also the uncertain interval between the removal of thymoma and the new onset MG. Additionally, some surgeons and anesthesiologists pay less attention to those asymptomatic thymoma patients in perioperative management, leading to the neglect of new onset PTMG, and miss the best time to treat it.

Case Presentation: Majority of cases of PTMG with onset at stage I-II on the basis of Myasthenia Gravis Foundation of America (MGFA) classification have been reported, but rarely at stage V, which requiring intubation or non-invasive ventilation to avoid intubation. Herein, we presented a 70-year-old male with PTMG onset at MGFA stage V, meanwhile, he had severe pulmonary infection interfering with the diagnosis of PTMG, and eventually progressed to refractory PTMG, which requiring much more expensive treatments and longer hospital stays.

Conclusion: In the perioperative management of asymptomatic thymoma patients, careful preoperative evaluation including physical examination, electrophysiological test and acetylcholine receptor antibodies (AChR-Ab) level should be done to identify subclinical MG. Complete resection should be performed during thymectomy, if not, additional postoperative adjuvant therapy is neccessary to avoid recurrence. It's important to identify PTMG at a early stage, especially when being interfered with by postoperative complications, such as lung infection, so that treatments could be initiated as soon as possible to avoid developing to refractory PTMG.

Download full-text PDF

 Source
http://dx.doi.org/10.1186/s13019-022-01872-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097348PMC
May 2022

Publication Analysis

Top Keywords

myasthenia gravis
16
thymoma patients
12
ptmg
9
onset mgfa
8
asymptomatic thymoma
8
perioperative management
8
refractory ptmg
8
mgfa stage
8
ptmg onset
8
post-thymectomy myasthenia
8
onset
5
stage
5
requiring expensive
4
70-year-old male
4
male ptmg
4
longer hospital
4
stage severe
4
severe pulmonary
4
pulmonary infection
4
interfering diagnosis
4

Keyword Occurance

Similar Publications

Subxiphoid and subcostal arch versus unilateral video-assisted thoracic surgery approaches to thymectomy for myasthenia gravis.

Authors:
Yujiang Li Zhenhui Huang Wohua Han Jingquan Yuan Ruiwen Xie Guobiao Cheng Xi'an Huang Yuliang Guo Mongying Sun Yali Liu Xu Wu Jianping Zhou

Surg Today 2022 Jul 1. Epub 2022 Jul 1.

Department of Thoracic and Cardiovascular Surgery, Affiliated Dongguan People's Hospital, Southern Medical University (Dongguan People's Hospital), No. 3, South of Wandao Road, Wanjiang District, Dongguan, 523000, China.

Purpose: Thymectomy is an important treatment for myasthenia gravis (MG). We conducted this study to compare the clinical outcomes of the recently introduced subxiphoid and subcostal arch thymectomy (SASAT) approach with those of the standard unilateral video-assisted thoracoscopic surgery (VATS).

Methods: We analyzed, retrospectively, the perioperative, and long-term outcomes of 179 consecutive MG patients (age 18-65 years), who underwent SASAT or unilateral VATS-extended thymectomy between July, 2012 and May, 2019. Read More

View Article and Full-Text PDF
July 2022
Similar Publications

Co-occurrence of Glycogen Storage Disease Type 2 and Congenital Myasthenic Syndrome Type 5 in a Pediatric Patient: A Case Report.

Authors:
Fawzia Al-Sharif Mohammed F Alamer Hussein O Taher Raneem Y Gazzaz Asma O AlRuwaithi Tuleen T Miliany Mohammed A Alrufaihi Abdullah F Al Amer

Cureus 2022 Jun 26;14(6):e26345. Epub 2022 Jun 26.

College of Medicine, Gulf Medical University, Ajman, ARE.

Glycogen storage disease type 2 (also known as Pompe disease) is a metabolic disorder characterized by an accumulation of glycogen within lysosomes. Pathophysiologically, this condition is caused by an autosomal recessive deficiency of the lysosomal acid alpha-glucosidase enzyme, resulting in defects in lysosomal metabolism. Glycogen accumulation causes advanced muscle weakness (myopathy) throughout the body, including the heart, skeletal muscles, liver, and the neurological system. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Long-Term Efficacy of Non-steroid Immunosuppressive Agents in Anti-Muscle-Specific Kinase Positive Myasthenia Gravis Patients: A Prospective Study.

Authors:
Ying Tan Jiayu Shi Yangyu Huang Ke Li Jingwen Yan Li Zhu Yuzhou Guan Liying Cui

Front Neurol 2022 13;13:877895. Epub 2022 Jun 13.

Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Background And Purpose: Anti-muscle-specific kinase (MuSK) positive myasthenia gravis (MG) is characterized by a high relapsing rate, thus, choosing the appropriate oral drug regimen is a challenge. This study aimed to evaluate the efficacy of oral immunosuppressants (IS) in preventing relapse in MuSK-MG.

Methods: This prospective cohort observational study included patients with MuSK-MG at Peking Union Medical College Hospital between January 1, 2018, and November 15, 2021. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Risk of Autoimmune Diseases Following Optic Neuritis: A Nationwide Population-Based Cohort Study.

Authors:
Kevin Sheng-Kai Ma Chee-Ming Lee Po-Hung Chen Yan Yang Yi Wei Dong Yu-Hsun Wang James Cheng-Chung Wei Wen Jie Zheng

Front Med (Lausanne) 2022 13;9:903608. Epub 2022 Jun 13.

Department of Pediatrics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.

Objectives: Optic neuritis is (ON) is believed to be an immune-mediated disease; however, the association between optic neuritis and autoimmune diseases remains unclear. This study aimed to identify the incidence rate and adjusted hazard ratio (aHR) of autoimmune diseases in patients with optic neuritis.

Methods: This nationwide, population-based, retrospective cohort study collected patients' data between 1999 and 2013 from the National Health Insurance Research Database in Taiwan. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Real-World Application of Plasmapheresis for Neurological Disease: Results from the Japan-Plasmapheresis Outcome and Practice Patterns Study (J-POPPS).

Authors:
Youwei Lin Satoru Oji Katsuichi Miyamoto Tomoko Narita Mana Kameyama Hidenori Matsuo

Ther Apher Dial 2022 Jun 29. Epub 2022 Jun 29.

Department of Neurology, Nagasaki Kawatana Medical Center.

Introduction: Plasmapheresis is a well-recognized treatment for autoimmune neurological diseases in Japan. However, the practice varies depending on the facility, and the actual treatment conditions are unclear.

Methods: To clarify real-world conditions, a prospective observational study was conducted on patients with neurological diseases who were scheduled to receive plasmapheresis. Read More

View Article and Full-Text PDF
June 2022
Similar Publications
}